Literature DB >> 16723564

Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.

E E McKee1, M Ferguson, A T Bentley, T A Marks.   

Abstract

The effects of a variety of oxazolidinones, with different antibacterial potencies, including linezolid, on mitochondrial protein synthesis were determined in intact mitochondria isolated from rat heart and liver and rabbit heart and bone marrow. The results demonstrate that a general feature of the oxazolidinone class of antibiotics is the inhibition of mammalian mitochondrial protein synthesis. Inhibition was similar in mitochondria from all tissues studied. Further, oxazolidinones that were very potent as antibiotics were uniformly potent in inhibiting mitochondrial protein synthesis. These results were compared to the inhibitory profiles of other antibiotics that function by inhibiting bacterial protein synthesis. Of these, chloramphenicol and tetracycline were significant inhibitors of mammalian mitochondrial protein synthesis while the macrolides, lincosamides, and aminoglycosides were not. Development of future antibiotics from the oxazolidinone class will have to evaluate potential mitochondrial toxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723564      PMCID: PMC1479116          DOI: 10.1128/AAC.01411-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

Review 1.  Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid.

Authors:  D J Kuter; G S Tillotson
Journal:  Pharmacotherapy       Date:  2001-08       Impact factor: 4.705

2.  Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement.

Authors:  A M Lovering; J Zhang; G C Bannister; B J A Lankester; J H M Brown; G Narendra; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

3.  The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class.

Authors:  Richard J Sciotti; Marina Pliushchev; Paul E Wiedeman; Darlene Balli; Robert Flamm; Angela M Nilius; Kennan Marsh; DeAnne Stolarik; Robert Jolly; Roger Ulrich; Stevan W Djuric
Journal:  Bioorg Med Chem Lett       Date:  2002-08-19       Impact factor: 2.823

4.  In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.

Authors:  Eun Jeong Yoon; Yeong Woo Jo; Sung Hak Choi; Tae Ho Lee; Jae Keol Rhee; Moohi Yoo; Mi Ja Shim; Eung Chil Choi
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Haemotoxicity of thiamphenicol in the BALB/c mouse and Wistar Hanover rat.

Authors:  J A Turton; C M Andrews; A C Havard; S Robinson; M York; T C Williams; F M Gibson
Journal:  Food Chem Toxicol       Date:  2002-12       Impact factor: 6.023

6.  Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.

Authors:  M J Genin; D A Allwine; D J Anderson; M R Barbachyn; D E Emmert; S A Garmon; D R Graber; K C Grega; J B Hester; D K Hutchinson; J Morris; R J Reischer; C W Ford; G E Zurenko; J C Hamel; R D Schaadt; D Stapert; B H Yagi
Journal:  J Med Chem       Date:  2000-03-09       Impact factor: 7.446

7.  Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.

Authors:  I Chopra; M Roberts
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

8.  1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes.

Authors:  Casey Chun Zhou; Steven M Swaney; Dean L Shinabarger; Brian J Stockman
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes.

Authors:  Hiroyuki Aoki; Lizhu Ke; Susan M Poppe; Toni J Poel; Elizabeth A Weaver; Robert C Gadwood; Richard C Thomas; Dean L Shinabarger; M Clelia Ganoza
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

10.  Hematologic effects of linezolid: summary of clinical experience.

Authors:  Stanton L Gerson; Sheldon L Kaplan; Jon B Bruss; Vu Le; Felix M Arellano; Barry Hafkin; David J Kuter
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

View more
  81 in total

1.  Survival in critical illness is associated with early activation of mitochondrial biogenesis.

Authors:  Jane E Carré; Jean-Christophe Orban; Lorenza Re; Karen Felsmann; Wiebke Iffert; Michael Bauer; Hagir B Suliman; Claude A Piantadosi; Terry M Mayhew; Patrick Breen; Martin Stotz; Mervyn Singer
Journal:  Am J Respir Crit Care Med       Date:  2010-06-10       Impact factor: 21.405

2.  Rhabdomyolysis in a patient treated with linezolid for extensively drug-resistant tuberculosis.

Authors:  Matthew W Carroll; Hongjo Choi; Seonyeong Min; Soohee Hwang; Hyeeun Park; Taeksun Song; Yumi Park; Han-Seung Jeon; Lisa C Goldfeder; Laura E Via; Janette Lebron; Boyoung Jin; Ying Cai; Clifton E Barry; Myungsun Lee
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

3.  Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.

Authors:  Robert S Wallis; Wesley Jakubiec; Vikas Kumar; Gabriella Bedarida; Annette Silvia; Darcy Paige; Tong Zhu; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Paul F Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.

Authors:  J W C Alffenaar; T van der Laan; S Simons; T S van der Werf; P J van de Kasteele; H de Neeling; D van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

Review 5.  A Coming of Age Story: Chlamydia in the Post-Genetic Era.

Authors:  Anna J Hooppaw; Derek J Fisher
Journal:  Infect Immun       Date:  2015-12-14       Impact factor: 3.441

6.  Oxazolidinones and human immunodeficiency virus.

Authors:  Miguel G Madariaga; Susan Swindells; E E McKee
Journal:  Antimicrob Agents Chemother       Date:  2007-03       Impact factor: 5.191

7.  Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation.

Authors:  Shankar S Iyer; Qiong He; John R Janczy; Suzanne L Cassel; Fayyaz S Sutterwala; Eric I Elliott; Zhenyu Zhong; Alicia K Olivier; Jeffrey J Sadler; Vickie Knepper-Adrian; Renzhi Han; Liang Qiao; Stephanie C Eisenbarth; William M Nauseef
Journal:  Immunity       Date:  2013-08-15       Impact factor: 31.745

Review 8.  New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.

Authors:  Masayuki Igarashi; Yoshimasa Ishizaki; Yoshiaki Takahashi
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

9.  Assessing neuronal bioenergetic status.

Authors:  Stephanie L H Zeiger; Jeannette N Stankowski; BethAnn McLaughlin
Journal:  Methods Mol Biol       Date:  2011

10.  Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.

Authors:  Alex Soriano; Mar Ortega; Sebastián García; Georgina Peñarroja; Albert Bové; Miguel Marcos; Juan C Martínez; José A Martínez; Josep Mensa
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.